Form 4: Modular Medical Executives and Entities Report Stock Option and Warrant Transactions

Multiple executives and entities associated with Modular Medical, Inc. reported transactions involving stock options and warrants, including new grants tied to FDA submission and manufacturing milestones.

Summary

• This document is a Form 4 filing with the SEC, detailing changes in beneficial ownership of Modular Medical, Inc. [MODD] securities.
• The reporting parties include Manchester Management Co LLC, Manchester Management PR, LLC, James E. Besser, Morgan C. Frank, Manchester Explorer, L.P., and JEB Partners, L.P.
• The transactions primarily involve the acquisition of stock options and warrants.
• James E. Besser, as Managing Member, signed on behalf of Manchester Management Co LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., and JEB Partners, L.P.
• Morgan C. Frank also signed individually.
• New options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program.
• The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option and warrant transactions. The vesting conditions tied to milestones are mildly positive, suggesting progress towards company goals.

Positives

• The granting of options to management and directors aligns their interests with the company's success.
• The vesting of options is tied to specific milestones related to FDA submission and manufacturing validation, incentivizing progress towards key goals.
• The Outside Director Compensation Plan provides vested options on the grant date.

Risks

• Failure to meet the FDA submission deadline of October 31, 2025, or the manufacturing validation deadline of March 15, 2026, would result in the forfeiture of a portion of the granted options.
• The value of the options and warrants is dependent on the future performance of Modular Medical's stock price.

Future Outlook

The vesting of new options is contingent upon achieving specific milestones related to FDA submission and manufacturing validation for the MODDi product.

Industry Context

This filing is typical for publicly traded companies and provides transparency regarding the ownership of securities by insiders.

Stakeholder Impact

• Shareholders may view the granting of options as a positive sign, aligning management's interests with the company's success.
• Employees who are option holders are incentivized to contribute to the achievement of the company's milestones.

Next Steps

• The company needs to meet the FDA submission deadline of October 31, 2025, and the manufacturing validation deadline of March 15, 2026, to ensure the vesting of the granted options.
• Monitor the company's progress towards these milestones.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, warrants, Modular Medical, MODD, James E. Besser, Morgan C. Frank, Manchester Management, FDA submission, manufacturing validation